BridgeBio has significantly advanced the course of the new therapy for amyloid heart disease, leveraging the investigational drug. Initial clinical results indicates significant benefits for patients diagnosed with the https://attruby895677.diowebhost.com/97357269/company-progresses-amyloidosis-therapy-with-attruby